Human Genome Sciences (NASDAQ:HGSI)

CAPS Rating: 2 out of 5

The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease.

Recs

1
Player Avatar jeffrycooks (69.40) Submitted: 1/18/2012 8:17:47 PM : Outperform Start Price: $9.06 HGSI Score: +49.55

yes to rl

Featured Broker Partners


Advertisement